Výsledky vyhledávání - "Shkun Chadda"

Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence

Autor: Kathleen Bowes, Nick Jovanoski, Audrey E. Brown, Danilo Di Maio, Rossella Belleli, Shkun Chadda, Seye Abogunrin

Publikováno v: Medical Oncology. 40

Approximately 10–50% of patients treated for early-stage (I–III), resectable non-small cell lung cancer (eNSCLC) will develop locoregional recurrence. There is a lack of prospective trials evaluating optimal post-surgery follow-up for this patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::135b55022871784145df532ad03d4246
https://doi.org/10.1007/s12032-022-01790-0

Zobrazit plný text záznamu

Early introduction of a semi-elemental formula may be cost saving compared to a polymeric formula among critically ill patients requiring enteral nutrition: a cohort cost–consequence model

Autor: Aurelie Danel, Douglas L. Nguyen, Alistair S Curry, Shkun Chadda

Publikováno v: ClinicoEconomics and Outcomes Research: CEOR

Alistair S Curry,1 Shkun Chadda,1 Aurélie Danel,2 Douglas L Nguyen3 1Health Economics, SIRIUS Market Access, London UK; 2Market Access, Nestlé Health Science, Vevey, Switzerland; 3University of California-Irvine Department of Medicine, Orange, CA,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b665d8e36da7ddebf9c9032ef043a88
http://europepmc.org/articles/PMC5993029

Zobrazit plný text záznamu

The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: A European perspective

Autor: Sue Gao, David Sykes, Mark Larkin, Nils-Olof Bengttson, Zhongyun Zhao, Clare Jones, Shkun Chadda, Beth Barber

Publikováno v: Journal of Oncology Pharmacy Practice. 19:38-47

Background and objectives: Published data on the clinical and economic impact of infusion reactions to monoclonal antibodies are limited. This study investigated oncologists’ and oncology nurses’ opinions about resource use associated with infusi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8783fff29d067010fe80b1295860ea6f
https://doi.org/10.1177/1078155212451197

Zobrazit plný text záznamu

Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments

Autor: Peter Sajosi, Julie Winstone, Stephen Ralston, Shkun Chadda

Publikováno v: Orphanet Journal of Rare Diseases

Background Clinical trials for treatments indicated for orphan diseases may be limited due to the low prevalence of such diseases; this can result in implications for both regulatory and health economic perspectives. This study assessed the pivotal c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f5f04cc4d7bae67d121771913bbb46
https://pubmed.ncbi.nlm.nih.gov/26511061

Zobrazit plný text záznamu

Time to Second Objective Disease Progression (PFS2): An Emerging Clinical Trial Endpoint with Regulatory and Reimbursement Implications

Autor: Zacharie Mbanya, Shkun Chadda

Publikováno v: Blood. 124:6005-6005

Introduction: Overall survival (OS) continues to be the preferred endpoint for measuring sustained clinical benefits in oncology trials. In some cases, measuring OS can be problematical due to trial design, multiple lines of treatment (Tx), long surv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9c8c78e3ab74870a1a203205cd474a9
https://doi.org/10.1182/blood.v124.21.6005.6005

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání